Lungs Hurt Biography
(Source google.com)
Pleurisy
(also known as pleuritis) is an inflammation of the pleura, the lining
surrounding the lungs. There are many possible causes of pleurisy but
viral infections spreading from the lungs to pleural cavity are the most
common. The inflamed pleural layers rub against each other every time
the lungs expand to breathe in air. This can cause sharp pain when
breathing, also called pleuritic chest pain. The defining symptom of
pleurisy is a sudden sharp, stabbing, burning or dull pain in the right
or left side of the chest during breathing, especially when one inhales
and exhales. It feels worse with deep breathing, coughing, sneezing, or
laughing. The pain may stay in one place, or it may spread to the
shoulder or back. Sometimes, it becomes a fairly constant dull ache.
Depending on its cause, pleuritic chest pain may be accompanied by other symptoms: High-altitude pulmonary edema (HAPE) (spelled oedema in British English) is a life-threatening form of non-cardiogenic pulmonary edema (fluid accumulation in the lungs) that occurs in otherwise healthy mountaineers at altitudes typically above 2,500 meters (8,200 ft). Some cases, however, have been reported also at lower altitudes (between 1,500–2,500 metres or 4,900–8,200 feet in highly vulnerable subjects), although what makes some people susceptible to HAPE is not currently known. HAPE remains the major cause of death related to high-altitude exposure, with a high mortality rate in the absence of adequate emergency treatment. The incidence of clinical HAPE in unacclimatized travelers exposed to high altitude (~4,000 m or 13,000 ft) appears to be less than 1%. The U.S. Army Pike's Peak Research Laboratory has exposed sea-level-resident volunteers rapidly and directly to high altitude; during 30 years of research involving about 300 volunteers (and over 100 staff members), only three have been evacuated with suspected HAPE. Individual susceptibility to HAPE is difficult to predict. The most reliable risk factor is previous susceptibility to HAPE, and there is likely to be a genetic basis to this condition, perhaps involving the gene for angiotensin converting enzyme (ACE) Recently, scientists have found the similarities between low amounts of 2,3-BPG (also known as 2,3-DPG) with the occurrence of HAPE at high altitudes. Persons with sleep apnea are susceptible due to irregular breathing patterns while sleeping at high altitudes. In order to help understand the factors that make some individuals susceptible to HAPE, the International HAPE Database was set up in 2004. Individuals who have previously suffered from HAPE can register with this confidential database in order to help researchers study the condition. The standard and most important treatment is to descend to lower altitude as quickly as possible, preferably by at least 1000 metres. Oxygen should also be given if possible. Symptoms tend to quickly improve with descent, but more severe symptoms may continue for several days. The standard drug treatments for which there is strong clinical evidence are dexamethasone and nifedipine. Phosphodiesterase inhibitors such as sildenafil and tadalafil are also effective but may worsen the headache of mountain sickness.
The American Cancer Society says that lung cancer makes up 14% of all newly diagnosed cancers in the USA today. It adds that annually, more patients die from lung cancer alone than prostate, breast and colon cancers combined (in the USA). An American man’s lifetime risk of developing lung cancer is 1 in 13; for a woman the risk is 1 in 16. These risk figures are for all US adults, including smokers, ex-smokers and non-smokers. The risk for a regular smoker is dramatically higher. Most lung cancer patients are over the age of 60 years when they are diagnosed. Lung cancer takes several years to reach a level where symptoms are felt and the sufferer decides to seek medical help.
Depending on its cause, pleuritic chest pain may be accompanied by other symptoms: High-altitude pulmonary edema (HAPE) (spelled oedema in British English) is a life-threatening form of non-cardiogenic pulmonary edema (fluid accumulation in the lungs) that occurs in otherwise healthy mountaineers at altitudes typically above 2,500 meters (8,200 ft). Some cases, however, have been reported also at lower altitudes (between 1,500–2,500 metres or 4,900–8,200 feet in highly vulnerable subjects), although what makes some people susceptible to HAPE is not currently known. HAPE remains the major cause of death related to high-altitude exposure, with a high mortality rate in the absence of adequate emergency treatment. The incidence of clinical HAPE in unacclimatized travelers exposed to high altitude (~4,000 m or 13,000 ft) appears to be less than 1%. The U.S. Army Pike's Peak Research Laboratory has exposed sea-level-resident volunteers rapidly and directly to high altitude; during 30 years of research involving about 300 volunteers (and over 100 staff members), only three have been evacuated with suspected HAPE. Individual susceptibility to HAPE is difficult to predict. The most reliable risk factor is previous susceptibility to HAPE, and there is likely to be a genetic basis to this condition, perhaps involving the gene for angiotensin converting enzyme (ACE) Recently, scientists have found the similarities between low amounts of 2,3-BPG (also known as 2,3-DPG) with the occurrence of HAPE at high altitudes. Persons with sleep apnea are susceptible due to irregular breathing patterns while sleeping at high altitudes. In order to help understand the factors that make some individuals susceptible to HAPE, the International HAPE Database was set up in 2004. Individuals who have previously suffered from HAPE can register with this confidential database in order to help researchers study the condition. The standard and most important treatment is to descend to lower altitude as quickly as possible, preferably by at least 1000 metres. Oxygen should also be given if possible. Symptoms tend to quickly improve with descent, but more severe symptoms may continue for several days. The standard drug treatments for which there is strong clinical evidence are dexamethasone and nifedipine. Phosphodiesterase inhibitors such as sildenafil and tadalafil are also effective but may worsen the headache of mountain sickness.
The American Cancer Society says that lung cancer makes up 14% of all newly diagnosed cancers in the USA today. It adds that annually, more patients die from lung cancer alone than prostate, breast and colon cancers combined (in the USA). An American man’s lifetime risk of developing lung cancer is 1 in 13; for a woman the risk is 1 in 16. These risk figures are for all US adults, including smokers, ex-smokers and non-smokers. The risk for a regular smoker is dramatically higher. Most lung cancer patients are over the age of 60 years when they are diagnosed. Lung cancer takes several years to reach a level where symptoms are felt and the sufferer decides to seek medical help.
Lungs Hurt Lungs Diagram of a Smoker after Smoking Cancer Anatomy And Heart Drawing Images AFter Smoking Wee of a Weed Smoker
Lungs Hurt Lungs Diagram of a Smoker after Smoking Cancer Anatomy And Heart Drawing Images AFter Smoking Wee of a Weed Smoker
Lungs Hurt Lungs Diagram of a Smoker after Smoking Cancer Anatomy And Heart Drawing Images AFter Smoking Wee of a Weed Smoker
No comments:
Post a Comment